Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.71 HKD | -0.89% | -2.19% | +0.45% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.45% | 601M | |
+48.39% | 779B | |
-6.13% | 354B | |
+20.61% | 333B | |
+10.00% | 301B | |
+17.68% | 249B | |
-2.00% | 216B | |
+11.06% | 214B | |
+5.80% | 163B | |
-2.50% | 159B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Therapeutics' Phase 2 Trial for Dry Eye Treatment Meets Clinical Endpoints